These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22484993)

  • 1. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
    Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M; Álvarez E; Olivares JM; Carrasco JL; Ferro MB; Rejas J
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.
    Chollet J; Saragoussi D; Clay E; François C
    Value Health; 2013 Dec; 16(8):1133-9. PubMed ID: 24326166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
    Iskedjian M; Walker JH; Bereza BG; Le Melledo JM; Einarson TR
    Curr Med Res Opin; 2008 May; 24(5):1539-48. PubMed ID: 18416886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human and economic burden of generalized anxiety disorder.
    Hoffman DL; Dukes EM; Wittchen HU
    Depress Anxiety; 2008; 25(1):72-90. PubMed ID: 17146763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis.
    François C; Despiégel N; Maman K; Saragoussi D; Auquier P
    J Med Econ; 2010 Mar; 13(1):99-109. PubMed ID: 20078336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.
    Berger A; Edelsberg J; Bollu V; Alvir JM; Dugar A; Joshi AV; Oster G
    BMC Psychiatry; 2011 Dec; 11():193. PubMed ID: 22151689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.
    Berger A; Edelsberg J; Treglia M; Alvir JM; Oster G
    BMC Psychiatry; 2012 Oct; 12():177. PubMed ID: 23088742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain.
    Aranda-Reneo I; Oliva-Moreno J; Peña-Longobardo LM; Villar-Hernández ÁR; López-Bastida J
    Orphanet J Rare Dis; 2024 Sep; 19(1):352. PubMed ID: 39313783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social/economic costs and quality of life in patients with haemophilia in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care.
    Eveleigh R; Grutters J; Muskens E; Oude Voshaar R; van Weel C; Speckens A; Lucassen P
    Fam Pract; 2014 Oct; 31(5):578-84. PubMed ID: 25121977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder.
    Ikic V; Belanger C; Bouchard S; Gosselin P; Langlois F; Labrecque J; Dugas MJ; Marchand A
    J Ment Health Policy Econ; 2017 Mar; 20(1):11-20. PubMed ID: 28418834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():19-29. PubMed ID: 27038625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting].
    Sicras-Mainar A; Blanca-Tamayo M; Gutiérrez-Nicuesa L; Salvatella-Pasant J; Navarro-Artieda R
    Gac Sanit; 2010; 24(1):13-9. PubMed ID: 19646795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL; Álvarez E; Olivares JM; Rejas J
    Actas Esp Psiquiatr; 2013; 41(3):164-74. PubMed ID: 23803800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder.
    Zhu B; Zhao Z; Ye W; Marciniak MD; Swindle R
    J Nerv Ment Dis; 2009 Feb; 197(2):136-9. PubMed ID: 19214050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden.
    Sandelin R; Kowalski J; Ahnemark E; Allgulander C
    Eur Psychiatry; 2013 Feb; 28(2):125-33. PubMed ID: 22542328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-outcome of anxiety treatment intervention in primary care in Hungary.
    Zámbori J; Szádóczky E; Rózsa S; Füredi J
    J Ment Health Policy Econ; 2002 Sep; 5(3):115-20. PubMed ID: 12728198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.